Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas

Am J Pathol. 1994 Aug;145(2):287-93.


Alterations in the p53 gene have been described in a variety of human malignant neoplasms. We have examined 29 stage B prostate carcinomas for alterations in the p53 gene and for amplification of the MDM-2 gene. No evidence of mutations in the conserved exons 5 to 8 was found by polymerase chain reaction single-stranded conformation polymorphism analysis and no accumulation of p53 protein was found by immunohistochemistry. However, loss of heterozygosity at the p53 locus was observed in 11% of information cases. Amplification of the MDM-2 gene was not observed by Southern blot hybridization. In contrast, stage C and D prostate carcinomas showed accumulation of p53 protein in 33 to 66% of cases. We conclude that alterations in p53 function are infrequent in clinically localized prostate cancers but are more common in advanced cancers.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Chromosome Mapping
  • DNA, Neoplasm / genetics
  • DNA, Single-Stranded / genetics
  • Exons
  • Gene Amplification
  • Genes*
  • Heterozygote
  • Humans
  • Immunohistochemistry
  • Male
  • Neoplasm Proteins / genetics*
  • Neoplasm Staging
  • Nuclear Proteins*
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Proto-Oncogene Proteins c-mdm2
  • Proto-Oncogene Proteins*
  • Tumor Suppressor Protein p53 / genetics*


  • DNA, Neoplasm
  • DNA, Single-Stranded
  • Neoplasm Proteins
  • Nuclear Proteins
  • Proto-Oncogene Proteins
  • Tumor Suppressor Protein p53
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2